At BASEL INKUBATOR young entrepreneurs from the field of natural sciences, medicine, information technology and engineering technology can take their first steps towards creating a start-up. As long as there is free space available, start-ups from other fields are also welcome at BASEL INKUBATOR.
Our differentiated coaching will help you on your way to success. Support is provided in creating your business plan, and experts are on hand to guide you through specialist areas like making presentations and financial planning. Our experts will not do the work for you, but offer targeted support to help you create the foundations of your start-up for yourself.
BASEL INKUBATOR provides workspace in the open-plan office or individual offices as well as laboratory space at favourable prices.
BASEL INKUBATOR is more than just a workspace with the necessary infrastructure. A place for your corporate nameplate, a mailing address along with a real mailbox, a fully equipped meeting room for your presentations to investors and clients all give your start-up an identity.
ABBA Therapeutics AG is committed to novel antibody drug discovery that overcomes clinical resistance to targeted cancer therapies.
AlloCyte Pharmaceuticals AG is a Swiss-based pharmaceutical company that identifies, characterizes and validates novel drugs and therapeutic regimens for diseases of high medical need.
Development of antibody drug conjugates (ADC) to treat tumors. Antibodies are linked with toxins that are then released in the tumor and subsequently destroy it (apoptosis).
Cardiolynx focuses on novel treatments for cardio-metabolic diseases, a broad therapeutic area with high unmet medical need and significant growth potential.
High performance signal data processing for application in medical and biologic devices.
INOFEA develops and commercializes innovative nanomaterials for the detection and removal of environmental pollutants.
MiniNaviDent AG was founded by two oral- and cranio-maxillofacial surgeons from University Hospital Basel and two medtech engineers to develop a 3D guided surgery system for dental implantology.
Polyneuron is developing a new drug class and a promising therapeutic approach for autoimmune diseases. The new therapeutic approach is based on Polyneuron’s Antibody-Catch® platform that enables the selective neutralization of harmful autoantibodies.
Every year 1 - 2 million new cases of invasive fungal infections occur globally. Current therapies have many limitations and resistance is increasing. Selmod GmbH develops novel drugs for the treatment of life-threatening invasive fungal infections addressing resistance development and limitations of current therapies.
Nanomaterials for medical diagnosis and therapy
Feel free to contact us. Werner Enz will be happy to talk to you.
Dr. Werner M. Enz
CH 4057 Basel
T +41 61 633 30 10
F +41 61 633 30 11